Lista de obras - Brian D Lehmann - Dominio Público Uruguay

A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments

artículo científico publicado en 2015

A data similarity-based strategy for meta-analysis of transcriptional profiles in cancer

artículo científico publicado en 2013

A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells.

artículo científico publicado en 2007

Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer

artículo científico publicado en 2015

Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes

artículo científico publicado en 2021

Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy

artículo científico publicado en 2008

Attenuation of myocardial injury in mice with functional deletion of the circadian rhythm gene mPer2

artículo científico publicado en 2010

BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition

artículo científico publicado en 2013

Clinical implications of molecular heterogeneity in triple negative breast cancer.

artículo científico publicado en 2015

Comparative study of exome copy number variation estimation tools using array comparative genomic hybridization as control

artículo científico publicado en 2013

Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells

artículo científico publicado en 2011

Detection of internal exon deletion with exon Del.

artículo científico publicado en 2014

Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes

artículo científico publicado en 2013

Distinct roles for p107 and p130 in Rb-independent cellular senescence

artículo científico publicado en 2008

Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies

artículo científico publicado en 2016

Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value

artículo científico publicado en 2015

Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.

artículo científico publicado en 2016

Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes

artículo científico publicado en 2014

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

artículo científico publicado en 2011

Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer

artículo científico publicado en 2013

Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer

artículo científico publicado en 2014

Mitochondria sequence mapping strategies and practicability of mitochondria variant detection from exome and RNA sequencing data.

artículo científico publicado en 2015

Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets

artículo científico publicado en 2013

Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes

artículo científico publicado en 2021

Multi-perspective quality control of Illumina exome sequencing data using QC3.

artículo científico publicado en 2014

New strategies for triple-negative breast cancer--deciphering the heterogeneity

artículo científico publicado en 2014

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

artículo científico publicado en 2014

Patient-derived breast tumor xenografts facilitating personalized cancer therapy

artículo científico publicado en 2013

Practicality of identifying mitochondria variants from exome and RNAseq data.

artículo científico publicado en 2015

RNA Sequencing of Formalin-Fixed, Paraffin-Embedded Specimens for Gene Expression Quantification and Data Mining

artículo científico publicado en 2016

RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.

artículo científico publicado en 2010

RNAseq by Total RNA Library Identifies Additional RNAs Compared to Poly(A) RNA Library

artículo científico publicado en 2015

Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway.

artículo científico publicado en 2007

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.

artículo científico publicado en 2016

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

artículo científico publicado en 2007

SPARCL1 suppresses metastasis in prostate cancer.

artículo científico publicado en 2013

Senescence-associated exosome release from human prostate cancer cells.

artículo científico publicado en 2008

Subtyping of triple-negative breast cancer: implications for therapy

artículo científico publicado en 2014

Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.

artículo científico publicado en 2008

TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer.

artículo científico publicado en 2012

Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors

scientific article published on 01 March 2020

Targeting mutant p53 in human tumors

artículo científico

Targeting prostate cancer based on signal transduction and cell cycle pathways.

artículo científico publicado en 2008

Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

artículo científico publicado en 2007

Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer.

artículo científico publicado en 2014

Triple-negative breast cancer: molecular subtypes and new targets for therapy.

artículo científico publicado en 2015

p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3.

artículo científico publicado en 2012

Lista de obras de Brian D Lehmann

A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments

A data similarity-based strategy for meta-analysis of transcriptional profiles in cancer

A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells.

Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer

Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes

Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy

Attenuation of myocardial injury in mice with functional deletion of the circadian rhythm gene mPer2

BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition

Clinical implications of molecular heterogeneity in triple negative breast cancer.

Comparative study of exome copy number variation estimation tools using array comparative genomic hybridization as control

Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells

Detection of internal exon deletion with exon Del.

Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes

Distinct roles for p107 and p130 in Rb-independent cellular senescence

Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies

Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value

Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.

Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer

Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer

Mitochondria sequence mapping strategies and practicability of mitochondria variant detection from exome and RNA sequencing data.

Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets

Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes

Multi-perspective quality control of Illumina exome sequencing data using QC3.

New strategies for triple-negative breast cancer--deciphering the heterogeneity

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

Patient-derived breast tumor xenografts facilitating personalized cancer therapy

Practicality of identifying mitochondria variants from exome and RNAseq data.

RNA Sequencing of Formalin-Fixed, Paraffin-Embedded Specimens for Gene Expression Quantification and Data Mining

RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.

RNAseq by Total RNA Library Identifies Additional RNAs Compared to Poly(A) RNA Library

Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway.

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

SPARCL1 suppresses metastasis in prostate cancer.

Senescence-associated exosome release from human prostate cancer cells.

Subtyping of triple-negative breast cancer: implications for therapy

Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.

TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer.

Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors

Targeting mutant p53 in human tumors

Targeting prostate cancer based on signal transduction and cell cycle pathways.

Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer.

Triple-negative breast cancer: molecular subtypes and new targets for therapy.

p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3.